Latest Conference Articles

With more novel therapies entering the market, costs are on the rise, however, new research suggests that the price tag may not reflect the drug’s clinical value.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.

Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.

The addition of the immunotherapy pembrolizumab (Keytruda) to standard presurgical chemotherapy improved pathological complete response (pCR) rates for patients with triple-negative breast cancer (TNBC).

A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, talked about how ovarian cancer treatment has evolved over the years.

The PRIMA study evaluated the efficacy and safety of niraparib therapy after response to platinum-based chemotherapy in patients with newly-diagnosed ovarian cancer.

At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.

New data presented at the ESMO Congress 2019 showed that a 2-drug immunotherapy combination improved overall survival in patients with advanced non-small cell lung cancer.

At ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the latest practice-changing clinical data results involving PARP inhibitor therapy in ovarian cancer.

Five-year overall survival rates in patients with melanoma were 52% for nivolumab plus ipilimumab, 44% for nivolumab, and 26% for ipilimumab.  

The findings from 3 analyses on avelumab in combination with axitinib significantly improved progression-free survival compared with sunitinib in patients with advanced renal cell carcinoma.

First-line atezolizumab (Tecentriq, Roche) monotherapy demonstrated improved survival compared with chemotherapy alone in PD-L1-high non-small cell lung cancer.

The efficacy of ceritinib was evaluated in patients who have ALK-positive non-small cell lung cancer with active brain metastases.

Improvements in overall survival and response rates found in patients with advanced hepatocellular carcinoma treated with first-line nivolumab.

The European Society for Medical Oncology (ESMO) Congress 2019 will be taking place September 27 to October 1 in Barcelona, Spain, and Pharmacy Times® and Specialty Pharmacy Times® will be on location delivering coverage.

David Pope, PharmD, CDE, and chief innovation officer of OmniSYS, and John King, CEO of OmniSYS, discuss some opportunities to leverage cash prescriptions to drive revenue in the pharmacy.

David Pope, PharmD, CDE, chief innovation officer of OmniSYS, and John King, CEO of OmniSYS, discuss how they're tackling medication adherence concerns and how technology can provide a solution. This video was filmed at the 2019 NACDS Total Store Expo.

Jim Kirby, PharmD, BCPS, CDE, and senior director of pharmacy services for The Kroger Co., discusses how chain pharmacies have a unique opportunity in preventive care services.

David Pope, PharmD, CDE, and John King, CEO of OmniSYS, discuss how new opportunities for pharmacies are also creating new questions and needs.

Jim Kirby, PharmD, BCPS, CDE, and Sr. Director of Pharmacy Services for The Kroger Co., discusses his recommendations for implementing or expanding preventive care services in your pharmacy.

The multicultural population is increasing and thus creating a vital new market for pharmacies looking to grow and expand their services, said Mariko Carpenter, VP of Strategic Community Alliances at Nielsen, in a session at the 2019 NACDS Total Store Expo in Boston.

Jim Kirby, PharmD, BCPS, CDE, Sr. Director of Pharmacy Services for The Kroger Co., discusses what preventive care entails. This video was filmed at the 2019 NACDS Total Store Expo.

H-E-B, a supermarket chain based in San Antonio, Texas, received the 2019 PEP Award at a reception Friday evening in Boston, as part of the NACDS Total Store Expo.

John King, CEO, and David Pope, Chief Innovation Officer, of OmniSYS, discuss how they're tackling reimbursement issues for pharmacies.

Former Secretary of State John Kerry spoke about the need for bipartisan and international support during a business session at the 2019 NACDS Total Store Expo in Boston.

Attendees at the NACDS Total Store Expo in Boston had a chance to hear about the changing landscape of wellness, in a presentation titled “How To Get Your Share of the Big Business of WELL,” presented by representatives from WSL Strategic Retail.

Daniel Griffis, PharmD, pharmacy manager at Rainbow Drug Store, Brunswick, GA, sat down with Pharmacy Times to discuss the diabetes management system at the pharmacy.